Just before Thanksgiving, Innate Pharma SA announced its anti-KIR (killer-cell immunoglobulin-like receptor) drug lirilumab, which is licensed to Bristol-Myers Squibb Co., failed to provide clear evidence of benefit in a combination trial with Opdivo. It is further bad news for Innate as the drug also failed to demonstrate efficacy in a monotherapy trial earlier this year.
Innate's stock was down around 40% on Nov. 23, falling on the Paris stock exchange from more than €8 per...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)